Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.54 GBX | 0.00% | +9.66% | -18.46% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 01 | HSS Hire annual profit falls amid investment spending; CFO to depart | AN |
Sales 2024 * | 347M 440M | Sales 2025 * | 360M 455M | Capitalization | 67.26M 85.13M |
---|---|---|---|---|---|
Net income 2024 * | 6M 7.59M | Net income 2025 * | 7M 8.86M | EV / Sales 2024 * | 0.47 x |
Net Debt 2024 * | 95.22M 121M | Net Debt 2025 * | 99.75M 126M | EV / Sales 2025 * | 0.46 x |
P/E ratio 2024 * |
10.8
x | P/E ratio 2025 * |
9.55
x | Employees | 2,000 |
Yield 2024 * |
6.05% | Yield 2025 * |
6.23% | Free-Float | 24.68% |
1 week | +9.66% | ||
Current month | +15.50% | ||
1 month | +15.78% | ||
3 months | -1.55% | ||
6 months | -15.01% | ||
Current year | -18.46% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Ashmore
CEO | Chief Executive Officer | 60 | 17-05-31 |
Paul Quested
DFI | Director of Finance/CFO | 54 | 16-04-30 |
Daniel Joll
BRD | Director/Board Member | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 15-01-08 | |
Director/Board Member | 71 | 15-01-08 | |
Alan Peterson
CHM | Chairman | 77 | 12-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 9.54 | 0.00% | 405,904 |
24-05-15 | 9.54 | -2.65% | 773,106 |
24-05-14 | 9.8 | +4.26% | 2,802,554 |
24-05-13 | 9.4 | +4.91% | 1,234,380 |
24-05-10 | 8.96 | +2.99% | 1,473,699 |
Delayed Quote London S.E., May 16, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.46% | 85.2M | |
+18.79% | 47.44B | |
+10.51% | 33.65B | |
+22.00% | 17.99B | |
-10.99% | 7.61B | |
+17.76% | 5.59B | |
+4.85% | 4.52B | |
-3.22% | 3.68B | |
-9.30% | 2.67B | |
+17.76% | 2.18B |
- Stock Market
- Equities
- HSS Stock